Published in Exp Neurol on January 03, 2009
Tapping linked to function and structure in premanifest and symptomatic Huntington disease. Neurology (2010) 1.74
Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function. Neuroscience (2011) 1.62
Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease. Neuropsychiatr Dis Treat (2010) 1.06
A review of quality of life after predictive testing for and earlier identification of neurodegenerative diseases. Prog Neurobiol (2013) 1.03
Brain networks in Huntington disease. J Clin Invest (2011) 1.02
Impaired cortico-striatal functional connectivity in prodromal Huntington's Disease. Neurosci Lett (2012) 0.97
Metabolic network as a progression biomarker of premanifest Huntington's disease. J Clin Invest (2013) 0.95
Magnetic resonance perfusion imaging of resting-state cerebral blood flow in preclinical Huntington's disease. J Cereb Blood Flow Metab (2011) 0.92
Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis. Neurobiol Dis (2010) 0.91
Couples' attributions for work function changes in prodromal Huntington disease. J Genet Couns (2010) 0.90
Biomarkers to predict and track diseases. Lancet Neurol (2009) 0.83
Treatment of Huntington's disease. Neurotherapeutics (2014) 0.82
Depressive symptoms in prodromal Huntington's Disease correlate with Stroop-interference related functional connectivity in the ventromedial prefrontal cortex. Psychiatry Res (2012) 0.81
Neural correlates of impaired emotion processing in manifest Huntington's disease. Soc Cogn Affect Neurosci (2013) 0.80
The role of the amygdala during emotional processing in Huntington's disease: from pre-manifest to late stage disease. Neuropsychologia (2015) 0.79
Early Detection of Huntington Disease. Future Neurol (2010) 0.79
Striatal metabolism and psychomotor speed as predictors of motor onset in Huntington's disease. J Neurol (2014) 0.78
Functional connectivity modeling of consistent cortico-striatal degeneration in Huntington's disease. Neuroimage Clin (2015) 0.78
Regional vulnerability in Huntington's disease: fMRI-guided molecular analysis in patients and a mouse model of disease. Neurobiol Dis (2012) 0.78
Striatal hypometabolism in premanifest and manifest Huntington's disease patients. Eur J Nucl Med Mol Imaging (2016) 0.77
Neurophysiological and neurocognitive mechanisms underlying the effects of yoga-based practices: towards a comprehensive theoretical framework. Front Hum Neurosci (2015) 0.76
Frontal cortex BOLD signal changes in premanifest Huntington disease: a possible fMRI biomarker. Neurology (2014) 0.76
The Allure of High-Risk Rewards in Huntington's disease. J Int Neuropsychol Soc (2015) 0.75
Development of the Huntington disease work function scale. J Occup Environ Med (2012) 0.75
Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci (1986) 18.17
Imaging cognition II: An empirical review of 275 PET and fMRI studies. J Cogn Neurosci (2000) 11.10
Huntington disease. J Neuropathol Exp Neurol (1998) 6.54
Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat Genet (1993) 6.53
Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry (2007) 5.49
Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci (1999) 4.27
Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol (2006) 3.57
The cerebellum communicates with the basal ganglia. Nat Neurosci (2005) 3.27
Medial temporal lobe activations in fMRI and PET studies of episodic encoding and retrieval. Hippocampus (1999) 3.00
Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study. Lancet Neurol (2006) 2.99
Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology (2004) 2.81
Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study. Biol Psychiatry (2007) 2.71
Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain (2008) 2.40
Bilateral human fetal striatal transplantation in Huntington's disease. Neurology (2002) 2.34
Factors associated with slow progression in Huntington's disease. Arch Neurol (1991) 2.18
fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington's Disease. AJNR Am J Neuroradiol (2004) 2.10
Huntington's chorea. Deficiency of gamma-aminobutyric acid in brain. N Engl J Med (1973) 2.06
Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology (2005) 1.95
Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease. N Engl J Med (1990) 1.89
Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain (1998) 1.84
Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. J Nucl Med (2006) 1.83
Huntington's disease: the challenge for cell biologists. Trends Cell Biol (2000) 1.80
Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scan. Ann Neurol (1982) 1.77
Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. Arch Neurol (1996) 1.74
Value-dependent selection in the brain: simulation in a synthetic neural model. Neuroscience (1994) 1.69
Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain (1996) 1.64
Basal ganglia and cerebellar inputs to 'AIP'. Cereb Cortex (2004) 1.61
Macro-architecture of basal ganglia loops with the cerebral cortex: use of rabies virus to reveal multisynaptic circuits. Prog Brain Res (2004) 1.58
Longitudinal change in basal ganglia volume in patients with Huntington's disease. Neurology (1997) 1.56
Thalamic metabolism and symptom onset in preclinical Huntington's disease. Brain (2007) 1.54
Verbal episodic memory declines prior to diagnosis in Huntington's disease. Neuropsychologia (2007) 1.54
PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline. Ann Neurol (1986) 1.53
Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease. J Neurosci (2001) 1.52
Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. N Engl J Med (1987) 1.51
Metabolic correlates of levodopa response in Parkinson's disease. Neurology (2001) 1.50
Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. Brain (1990) 1.44
Dorsolateral prefrontal cortex dysfunction in presymptomatic Huntington's disease: evidence from event-related fMRI. Brain (2007) 1.42
Pharmacological imposition of sleep slows cognitive decline and reverses dysregulation of circadian gene expression in a transgenic mouse model of Huntington's disease. J Neurosci (2007) 1.41
Preclinical Huntington's disease: compensatory brain responses during learning. Ann Neurol (2006) 1.36
fMRI detection of early neural dysfunction in preclinical Huntington's disease. J Int Neuropsychol Soc (2007) 1.35
Functional brain changes in presymptomatic Huntington's disease. Ann Neurol (2004) 1.34
White matter volume and cognitive dysfunction in early Huntington's disease. Cogn Behav Neurol (2005) 1.34
Positron emission tomography in the early diagnosis of Huntington's disease. Neurology (1986) 1.33
Mitochondria in neurodegeneration: bioenergetic function in cell life and death. J Cereb Blood Flow Metab (1999) 1.33
Striatal volume loss in HD as measured by MRI and the influence of CAG repeat. Neurology (2001) 1.33
Morphology of the cerebral cortex in preclinical Huntington's disease. Am J Psychiatry (2007) 1.32
How can EEG/MEG and fMRI/PET data be combined? Hum Brain Mapp (2002) 1.23
Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann Neurol (1996) 1.23
Brain energy metabolism and dopaminergic function in Huntington's disease measured in vivo using positron emission tomography. Mov Disord (1986) 1.21
Expression of normal and mutant huntingtin in the developing brain. J Neurosci (1996) 1.21
Assessment of procedural learning and problem solving in schizophrenic patients by Tower of Hanoi type tasks. J Neuropsychiatry Clin Neurosci (1990) 1.20
Aberrant connectivity of lateral prefrontal networks in presymptomatic Huntington's disease. Exp Neurol (2008) 1.17
Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. Brain (1997) 1.15
Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain (2003) 1.13
PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain (1997) 1.12
Striatal neural grafting improves cortical metabolism in Huntington's disease patients. Brain (2003) 1.09
Neuropsychological correlates of brain atrophy in Huntington's disease: a magnetic resonance imaging study. Neuroradiology (1992) 1.08
Interpreting PET and fMRI measures of functional neural activity: the effects of synaptic inhibition on cortical activation in human imaging studies. Brain Res Bull (2001) 1.04
Huntington's disease progression. PET and clinical observations. Brain (1999) 1.04
Apoptosis in Huntington's disease. Prog Neuropsychopharmacol Biol Psychiatry (2003) 1.04
Central motor processing in Huntington's disease. A PET study. Brain (1997) 1.03
Huntington's disease. Cold Spring Harb Symp Quant Biol (1996) 1.02
Decreased frontal choline and neuropsychological performance in preclinical Huntington disease. Neurology (2007) 1.00
The use of transgenic and knock-in mice to study Huntington's disease. Cytogenet Genome Res (2003) 0.97
Investigating connectivity between the cerebellum and thalamus in schizophrenia using diffusion tensor tractography: a pilot study. Psychiatry Res (2008) 0.96
Functional connectivity of the prefrontal cortex in Huntington's disease. J Neurol Neurosurg Psychiatry (2006) 0.95
Increased cortical recruitment in Huntington's disease using a Simon task. Neuropsychologia (2007) 0.93
Altered functional MRI responses in Huntington's disease. Neuroreport (2002) 0.93
Normal caudate glucose metabolism in persons at risk for Huntington's disease. Arch Neurol (1987) 0.93
Computed tomographic, neurologic, and neuropsychological correlates of Huntington's disease. Int J Neurosci (1983) 0.91
Patterns of cerebral glucose utilization in Parkinson's disease and Huntington's disease. Ann Neurol (1984) 0.91
Multimodal imaging of residual function and compensatory resource allocation in cortical atrophy: a case study of parietal lobe function in a patient with Huntington's disease. Psychiatry Res (1999) 0.90
Dopamine D1 receptor number--a sensitive PET marker for early brain degeneration in Huntington's disease. Eur Arch Psychiatry Clin Neurosci (1994) 0.90
Functional MRI study of a serial reaction time task in Huntington's disease. Psychiatry Res (2004) 0.90
Neuropsychological and neuroradiological correlates in Huntington's disease. J Neurol Neurosurg Psychiatry (1988) 0.90
Local cerebral glucose utilization in symptomatic and presymptomatic Huntington's disease. Res Publ Assoc Res Nerv Ment Dis (1985) 0.90
Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial. Neurology (1999) 0.89
In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias. Neurology (1997) 0.86
Methodological and conceptual issues in functional magnetic resonance imaging: applications to schizophrenia research. Annu Rev Clin Psychol (2006) 0.86
Dopamine receptor properties in Parkinson's disease and Huntington's chorea evaluated by positron emission tomography using 11C-N-methyl-spiperone. Acta Neurol Scand (1987) 0.85
The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington's disease. Neurology (1987) 0.83
Positron emission tomography measures of benzodiazepine receptors in Huntington's disease. Ann Neurol (1993) 0.82
Benzodiazepine receptor binding in Huntington's disease: [11C]flumazenil uptake measured using positron emission tomography. Ann Neurol (2000) 0.81
Neural modeling and functional brain imaging: the interplay between the data-fitting and simulation approaches. Int Rev Neurobiol (2005) 0.78
[Functional imaging of cognitive processes in Huntington's disease and its presymptomatic mutation carriers]. Nervenarzt (2008) 0.76